Streetbeat News

Regulatory

BFRG

BullFrog AI Holdings, Inc. announced the issuance of an Australian patent for novel prodrugs of mebendazole for cancer treatment. The compounds, including BF-223, show improved solubility and bioavailability, addressing challenges in using mebendazole for oncology. This follows a U.S. patent issued in July 2023 and positive preclinical study results for glioblastoma treatment. The company aims to monetize this asset with strategic partners.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:15 pm

STLA

SIXT and Stellantis have announced a multi-billion euro agreement for SIXT to purchase up to 250,000 Stellantis vehicles by 2026 for its rental fleet in Europe and North America. The deal includes a variety of vehicle classes and propulsion types, including battery electric vehicles (BEVs), and aligns with both companies' decarbonization strategies. Deliveries will start in Q1 2024. The partnership also explores cooperation in data services and aims to enhance customer experience with connected vehicles and streamlined rental processes. Stellantis aims for a 100% BEV sales mix in Europe and 50% in the US by 2030, while SIXT targets a 70-90% electrified fleet in Europe by 2030.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:12 pm

SLDB

Solid Biosciences Inc. (NASDAQ:SLDB) has received FDA Orphan Drug Designation for its Duchenne muscular dystrophy gene therapy candidate, SGT-003. The company, which focuses on precision genetic medicines for neuromuscular and cardiac diseases, also received Fast Track Designation last month. Patient dosing for the Phase 1/2 clinical trial of SGT-003 is expected to begin in mid-to-late Q1 2024. SGT-003 features a novel capsid and muscle tropic vector, which may offer improved transduction and muscle resiliency. The Orphan Drug Designation provides benefits such as financial incentives and the potential for seven years of market exclusivity upon approval.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:08 pm

PGEN

Precigen has been granted Orphan Drug Designation by the European Commission for PRGN-2012, a treatment for Recurrent Respiratory Papillomatosis (RRP). This designation is expected to provide Precigen with certain benefits, including market exclusivity upon regulatory approval, assistance with clinical development, and reduced regulatory fees.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:07 pm

TAK

The FDA has approved Takeda's HYQVIA as a maintenance therapy for adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). HYQVIA is the only subcutaneous immunoglobulin infusion treatment for CIDP that can be administered monthly and can be self-administered after proper training. The approval is based on the Phase 3 ADVANCE-CIDP 1 study, which showed a significant difference in relapse rate in favor of HYQVIA versus placebo at 6 months. CIDP is a rare neuromuscular disorder that can cause weakness or loss of feeling in the arms and legs.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:05 pm

CLPT

ClearPoint Neuro has announced that the FDA has cleared its SmartFrame OR stereotactic system, a device designed to assist surgeons during brain surgeries. This clearance represents a significant milestone for the company, potentially leading to increased adoption of the system in hospitals and surgical centers.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:01 pm

SXTP

60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) has regained compliance with Nasdaq's minimum bid price requirement for continued listing on The Nasdaq Capital Market. The company's stock had previously failed to maintain the required $1.00 minimum bid price for 30 consecutive business days. Compliance was achieved by maintaining a closing bid price of $1.00 or more for at least 10 consecutive trading days, with a closing bid price of $1.09 on January 9, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 12:59 pm

BX

Blackstone Inc. (NYSE: BX) is planning to double its private equity team in Singapore within two years to capitalize on increasing deal opportunities in Southeast Asia. The expansion aims to bring Blackstone closer to its investor base in the region. The company is focusing on sectors such as technology, healthcare, consumer, financial services, and value-added industrial, targeting deals as small as $150 million. This move is part of a broader shift by financial investors away from China due to geopolitical tensions and a slow economic recovery.

Portfolio Pulse from Lekha Gupta

January 16, 2024 | 12:58 pm

ANSS

Trading on ANSS has been halted at 7:25:24 a.m. ET due to pending news. The halt is in place to manage market orderliness and investor protection pending the release of material information.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 12:25 pm

ADA-USD

BTC-USD

Vivek Ramaswamy, a pro-crypto entrepreneur, has ended his campaign for the Republican presidential nomination after a fourth-place finish in the Iowa caucuses. He plans to endorse Donald Trump and has been praised for his crypto-friendly policies, which include treating most cryptocurrencies as commodities and protecting digital wallets. Ryan Selkis and Charles Hoskinson have expressed support for Ramaswamy's stance on crypto regulation.

Portfolio Pulse from Mehab Qureshi

January 16, 2024 | 12:09 pm